Journal
MOLECULES
Volume 23, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/molecules23030543
Keywords
ziyuglycoside I (ZGS1); ziyuglycoside II (ZGS2); LC-MS/MS; pharmacokinetics; tissue distribution; excretion
Funding
- National Natural Science Foundation of China [81560638]
- Young Scientists Training Project of Jiangxi Province [20142BCB23022]
- China Postdoctoral Science Foundation [2017M612159]
- Jiangxi Province 5511 RD projects [20165BCB19009]
- Nanchang innovative talent team [[2016]173]
Ask authors/readers for more resources
Ziyuglycoside I (ZGS1) is a promising drug candidate for the treatment of leucopenia. Currently, information on ZGS1 and its in vivo metabolite ziyuglycoside II (ZGS2) is limited. The objective of this study was to investigate the pharmacokinetics, tissue distribution, and excretion of ziyuglycoside I (ZGS1) and its metabolite ziyuglycoside II (ZGS2) in rats. In our study, a simple and sensitive high-performance liquid chromatography-mass spectrometry (HPLC-MS/MS) method was established for simultaneous determination of ZGS1 and its metabolite for Sprague-Dawley rat pharmacokinetics studies. The method was validated following internationally-approved guidelines. The results presented in this study indicated that subcutaneous administration of ZGS1 prolonged its extension time and increased the area under the curve (AUC(o-t)) of ZGS2 during 0 to t minutes. In summary, in this study, the pharmacokinetic characteristics of ZGS1 and its metabolite ZGS2 were defined and its tissue distribution, and excretion in rats were described. Our finding may be beneficial for leucopenia drug that focus on ZGS1.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available